exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275682 RNA Name: hsa-miR-512-3p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 53666729 End Site(bp): 53666750 External Links: hsa-miR-512-3p

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand IFNAR1 chr21 33324429 33359864 + RAI14 chr5 34656328 34832612 + NAA16 chr13 41311267 41377030 + TOB2 chr22 41433494 41446801 - ASB1 chr2 238426742 238452250 + RIT1 chr1 155897808 155911404 - C9orf40 chr9 74946583 74952912 - STK40 chr1 36339624 36385896 - LETMD1 chr12 51047962 51060424 + IQSEC1 chr3 12897043 13283281 - COQ10B chr2 197453423 197475308 + ZCCHC3 chr20 297570 300321 + FAM120AOS chr9 93431441 93453581 - NSD2 chr4 1871393 1982207 + MTMR12 chr5 32226994 32312987 - ZNF28 chr19 52797408 52857600 - WASL chr7 123681943 123749003 - TOMM6 chr6 41787662 41789898 + AP3M1 chr10 74120255 74151063 - OCRL chrX 129539849 129592561 + SYVN1 chr11 65121780 65134533 - LONP2 chr16 48244300 48363122 + MID1IP1 chrX 38801432 38806537 + SBF1 chr22 50445000 50475035 - TNRC6A chr16 24610209 24827632 + RAB31 chr18 9708275 9862551 + UHRF1BP1 chr6 34792015 34883138 + ERMP1 chr9 5765076 5833117 - ATP6V1E1 chr22 17592136 17628749 - TRIB1 chr8 125430358 125438403 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001731 chr7 100731990 100738448 + hsa_circ_0000384 chr12 27867712 27877119 + hsa_circ_0001159 chr20 40161688 40179999 - hsa_circ_0001865 chr9 86292641 86293514 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC004687.1 chr17 58330884 58332508 - AC091564.7 chr11 6610883 6616594 - AC092718.4 chr16 81030770 81031485 + FGD5-AS1 chr3 14920347 14948424 - MIR497HG chr17 7015818 7019659 - NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.